Lead candidate

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
Tuesday, November 7, 2023
Molecule, Psychosis, Biomarker, Therapy, Rare, Biotechnology, Genetics, Psychiatry, Novo Nordisk, CNS, Deficit spending, Access, Mitsubishi Tanabe Pharma, Metabolism, Clinic, Lundbeck, Myenteric plexus, Lead candidate, Medicine, Drug discovery, Neurology, Maryland School, Cognitive deficit, University, Health, Brain, Roche, Kynurenine, Cognition, Pharmaceutical industry, Management, CIAS, Schizophrenia, Takeda, Pfizer, Series

NAARDEN, The Netherlands, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

Key Points: 
  • Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
  • Dr. Schwarcz pioneered the study of the kynurenine pathway in the brain, which established kynurenine’s substantive role in cognition and in the pathophysiology of schizophrenia.
  • Through the convergence of human genetics, biomarkers, and deep phenotyping, Kynexis is well-positioned to pursue a novel, precision psychiatry-based approach to develop KYN-5356 in CIAS.
  • Under the terms of the agreement, Kynexis has an exclusive worldwide license from MTPC to develop and commercialize KYN-5356 worldwide.

Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

Retrieved on: 
Thursday, January 26, 2023
Safety, Therapy, MHC, Clinic, ERAP, TCR, ERAP1, Series, ERAP2, Neoplasm, PD-1, Cancer, Oxford Sciences Enterprises, ...Continued, Patient, Lead candidate, Clinical trial, Series B banknotes, OXFORD, Vaccine, Wolf

OXFORD, United Kingdom, Jan. 24, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the closing of an oversubscribed $49 million Series B financing. The financing was co-led by Pfizer Ventures and Earlybird Venture Capital, and also included investment from new investors Oxford Science Enterprises and British Patient Capital and existing investors Canaan and Andera Partners. Proceeds will support the continued development of the company's first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens. This includes the anticipated advancement of the company's lead asset, GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023.

Key Points: 
  • Proceeds will support the continued development of the company's first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens.
  • This includes the anticipated advancement of the company's lead asset, GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023.
  • This flexibility further amplifies the potential breadth of impact these investigational therapeutics may have in treating patients."
  • In conjunction with the financing, Grey Wolf Therapeutics has announced several new appointees to its board of directors including: